Global Milbemycin Oxime API Supply, Demand and Key Producers, 2026-2032
Description
The global Milbemycin Oxime API market size is expected to reach $ 54.18 million by 2032, rising at a market growth of 6.3% CAGR during the forecast period (2026-2032).
Milbemime is a novel semi-synthetic macrolide anthelmintic, an oxime derivative of milbemime A3 and A4. The molecular weight of A3 oxime is 541.7, and that of A4 oxime is 555.7. In application, milbemime can be used alone or in combination with drugs such as nitenpyram, flufenoxuron, spinosad, and praziquantel to form compound preparations. These preparations are effective in controlling internal parasites such as canine heartworm, hookworm, roundworm, and whipworm, as well as external parasites such as folliculitis, lice, and fleas. Milbemime is an agonist of the γ-aminobutyric acid (GABA) neurotransmitter in nerve cells and can also bind to glutamate-gated chloride ion channels in the nerve and muscle cells of invertebrates. In both cases, it blocks the nerve signals of the parasites, ultimately leading to paralysis, loss of muscle contraction, cessation of feeding, and death of the parasite. In 2025, global sales of milbemycin oxime API reached approximately 2.5 tons, with an average price of about US$14,000 per kilogram. The industry's average gross profit margin exceeded 55%.
Against the backdrop of continuous upgrading of the global veterinary drug industry and rapid development of the pet economy, the stable supply and technological capabilities of core active pharmaceutical ingredients (APIs) are becoming crucial factors determining industry competitiveness. As a key active ingredient widely used in parasite control, Milbemycin API is gradually evolving from a single-function ingredient into a fundamental substance supporting the modern veterinary drug system, with its market value and strategic importance continuously increasing.
Milbemycin is a macrolide compound primarily used to kill internal and external parasites, and is widely used in deworming preparations for companion animals such as dogs and cats. Its mechanism of action is well-defined, its spectrum of action is broad, and its safety profile is high, making it one of the core components in current pet deworming drug systems. As the source of efficacy in formulations, the quality stability, purity control, and batch consistency of Milbemycin API directly affect the safety and market acceptance of downstream veterinary drug products, highlighting its fundamental role in the entire industry chain.
From a market structure perspective, global demand for Milbemycin-related formulations is highly correlated with the growth in the pet population and the increasing standardization of pet healthcare. With the increasing adoption of companion animals in households, growing awareness of medical care, and the growing popularity of regular deworming, the penetration rate of milbemime-based deworming products continues to rise in both mature and emerging markets. This trend provides stable and long-term demand support for the milbemime API market, making it one of the most promising segments in the veterinary drug API sector.
From the supply side, the production of milbemime API has certain technical and process barriers. Its synthetic route is complex, and process control requirements are high, placing high demands on the stability of fermentation or chemical synthesis processes, impurity control capabilities, and quality systems. This gives API companies with mature process accumulation and sound quality management systems a greater competitive advantage in the market. As global veterinary drug regulations become stricter, milbemime API suppliers that meet international standards and have continuous supply capabilities will find it easier to enter the supply chains of mainstream veterinary drug companies.
In terms of supply chain collaboration, milbemime API is gradually forming closer cooperative relationships with downstream formulation companies. Pharmaceutical formulation companies are increasingly demanding higher standards for the stability, compliance, and traceability of raw material sources. This has transformed active pharmaceutical ingredients (APIs) from price-driven products into crucial foundations for cooperation driven by quality and supply capacity. This shift is propelling the milbemime API market from fragmented competition to a quality-oriented approach and long-term partnerships.
Regional markets show stable demand for milbemime formulations in mature markets like Europe, the US, and Japan, with high requirements for API quality and compliance. Meanwhile, emerging markets in Asia and Latin America are experiencing more significant demand growth, driven by increasing pet numbers and the standardization of the veterinary drug market. As a major global production base for veterinary drug APIs, China is gradually enhancing its technological capabilities and international market participation in the milbemime API sector, possessing the potential to extend into higher segments of the global supply chain.
Looking ahead, the milbemime API market will focus more on high-quality, compliant, and large-scale supply capabilities. With the continuous improvement of veterinary drug regulations, competition among API companies regarding process stability, quality consistency, and international registration support capabilities will intensify further. Meanwhile, the development of companion animal medicine towards long-term and preventative medication will also bring continuous and stable demand growth for milbemoxime raw materials.
This report studies the global Milbemycin Oxime API production, demand, key manufacturers, and key regions.
This report is a detailed and comprehensive analysis of the world market for Milbemycin Oxime API and provides market size (US$ million) and Year-over-Year (YoY) Growth, considering 2025 as the base year. This report explores demand trends and competition, as well as details the characteristics of Milbemycin Oxime API that contribute to its increasing demand across many markets.
Highlights and key features of the study
Global Milbemycin Oxime API total production and demand, 2021-2032, (KG)
Global Milbemycin Oxime API total production value, 2021-2032, (USD Million)
Global Milbemycin Oxime API production by region & country, production, value, CAGR, 2021-2032, (USD Million) & (KG), (based on production site)
Global Milbemycin Oxime API consumption by region & country, CAGR, 2021-2032 & (KG)
U.S. VS China: Milbemycin Oxime API domestic production, consumption, key domestic manufacturers and share
Global Milbemycin Oxime API production by manufacturer, production, price, value and market share 2021-2026, (USD Million) & (KG)
Global Milbemycin Oxime API production by Type, production, value, CAGR, 2021-2032, (USD Million) & (KG)
Global Milbemycin Oxime API production by Application, production, value, CAGR, 2021-2032, (USD Million) & (KG)
This report profiles key players in the global Milbemycin Oxime API market based on the following parameters - company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Livzon Pharmaceutical Group Inc, Zhejiang Hisun Pharmaceutical Co., Ltd, Hubei Honch Pharmaceutical Co.,Ltd, JIANGSU LINGYUN PHARMACEUTICAL CO.，LTD, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the World Milbemycin Oxime API market
Detailed Segmentation:
Each section contains quantitative market data including market by value (US$ Millions), volume (production, consumption) & (KG) and average price (US$/KG) by manufacturer, by Type, and by Application. Data is given for the years 2021-2032 by year with 2025 as the base year, 2026 as the estimate year, and 2027-2032 as the forecast year.
Global Milbemycin Oxime API Market, By Region:
United States
China
Europe
Japan
South Korea
ASEAN
India
Rest of World
Global Milbemycin Oxime API Market, Segmentation by Type:
98% Purity
Purity Greater than 98%
Global Milbemycin Oxime API Market, Segmentation by Application:
Dog
Cat
Other
Companies Profiled:
Livzon Pharmaceutical Group Inc
Zhejiang Hisun Pharmaceutical Co., Ltd
Hubei Honch Pharmaceutical Co.,Ltd
JIANGSU LINGYUN PHARMACEUTICAL CO.，LTD
Key Questions Answered:
1. How big is the global Milbemycin Oxime API market?
2. What is the demand of the global Milbemycin Oxime API market?
3. What is the year over year growth of the global Milbemycin Oxime API market?
4. What is the production and production value of the global Milbemycin Oxime API market?
5. Who are the key producers in the global Milbemycin Oxime API market?
6. What are the growth factors driving the market demand?
Milbemime is a novel semi-synthetic macrolide anthelmintic, an oxime derivative of milbemime A3 and A4. The molecular weight of A3 oxime is 541.7, and that of A4 oxime is 555.7. In application, milbemime can be used alone or in combination with drugs such as nitenpyram, flufenoxuron, spinosad, and praziquantel to form compound preparations. These preparations are effective in controlling internal parasites such as canine heartworm, hookworm, roundworm, and whipworm, as well as external parasites such as folliculitis, lice, and fleas. Milbemime is an agonist of the γ-aminobutyric acid (GABA) neurotransmitter in nerve cells and can also bind to glutamate-gated chloride ion channels in the nerve and muscle cells of invertebrates. In both cases, it blocks the nerve signals of the parasites, ultimately leading to paralysis, loss of muscle contraction, cessation of feeding, and death of the parasite. In 2025, global sales of milbemycin oxime API reached approximately 2.5 tons, with an average price of about US$14,000 per kilogram. The industry's average gross profit margin exceeded 55%.
Against the backdrop of continuous upgrading of the global veterinary drug industry and rapid development of the pet economy, the stable supply and technological capabilities of core active pharmaceutical ingredients (APIs) are becoming crucial factors determining industry competitiveness. As a key active ingredient widely used in parasite control, Milbemycin API is gradually evolving from a single-function ingredient into a fundamental substance supporting the modern veterinary drug system, with its market value and strategic importance continuously increasing.
Milbemycin is a macrolide compound primarily used to kill internal and external parasites, and is widely used in deworming preparations for companion animals such as dogs and cats. Its mechanism of action is well-defined, its spectrum of action is broad, and its safety profile is high, making it one of the core components in current pet deworming drug systems. As the source of efficacy in formulations, the quality stability, purity control, and batch consistency of Milbemycin API directly affect the safety and market acceptance of downstream veterinary drug products, highlighting its fundamental role in the entire industry chain.
From a market structure perspective, global demand for Milbemycin-related formulations is highly correlated with the growth in the pet population and the increasing standardization of pet healthcare. With the increasing adoption of companion animals in households, growing awareness of medical care, and the growing popularity of regular deworming, the penetration rate of milbemime-based deworming products continues to rise in both mature and emerging markets. This trend provides stable and long-term demand support for the milbemime API market, making it one of the most promising segments in the veterinary drug API sector.
From the supply side, the production of milbemime API has certain technical and process barriers. Its synthetic route is complex, and process control requirements are high, placing high demands on the stability of fermentation or chemical synthesis processes, impurity control capabilities, and quality systems. This gives API companies with mature process accumulation and sound quality management systems a greater competitive advantage in the market. As global veterinary drug regulations become stricter, milbemime API suppliers that meet international standards and have continuous supply capabilities will find it easier to enter the supply chains of mainstream veterinary drug companies.
In terms of supply chain collaboration, milbemime API is gradually forming closer cooperative relationships with downstream formulation companies. Pharmaceutical formulation companies are increasingly demanding higher standards for the stability, compliance, and traceability of raw material sources. This has transformed active pharmaceutical ingredients (APIs) from price-driven products into crucial foundations for cooperation driven by quality and supply capacity. This shift is propelling the milbemime API market from fragmented competition to a quality-oriented approach and long-term partnerships.
Regional markets show stable demand for milbemime formulations in mature markets like Europe, the US, and Japan, with high requirements for API quality and compliance. Meanwhile, emerging markets in Asia and Latin America are experiencing more significant demand growth, driven by increasing pet numbers and the standardization of the veterinary drug market. As a major global production base for veterinary drug APIs, China is gradually enhancing its technological capabilities and international market participation in the milbemime API sector, possessing the potential to extend into higher segments of the global supply chain.
Looking ahead, the milbemime API market will focus more on high-quality, compliant, and large-scale supply capabilities. With the continuous improvement of veterinary drug regulations, competition among API companies regarding process stability, quality consistency, and international registration support capabilities will intensify further. Meanwhile, the development of companion animal medicine towards long-term and preventative medication will also bring continuous and stable demand growth for milbemoxime raw materials.
This report studies the global Milbemycin Oxime API production, demand, key manufacturers, and key regions.
This report is a detailed and comprehensive analysis of the world market for Milbemycin Oxime API and provides market size (US$ million) and Year-over-Year (YoY) Growth, considering 2025 as the base year. This report explores demand trends and competition, as well as details the characteristics of Milbemycin Oxime API that contribute to its increasing demand across many markets.
Highlights and key features of the study
Global Milbemycin Oxime API total production and demand, 2021-2032, (KG)
Global Milbemycin Oxime API total production value, 2021-2032, (USD Million)
Global Milbemycin Oxime API production by region & country, production, value, CAGR, 2021-2032, (USD Million) & (KG), (based on production site)
Global Milbemycin Oxime API consumption by region & country, CAGR, 2021-2032 & (KG)
U.S. VS China: Milbemycin Oxime API domestic production, consumption, key domestic manufacturers and share
Global Milbemycin Oxime API production by manufacturer, production, price, value and market share 2021-2026, (USD Million) & (KG)
Global Milbemycin Oxime API production by Type, production, value, CAGR, 2021-2032, (USD Million) & (KG)
Global Milbemycin Oxime API production by Application, production, value, CAGR, 2021-2032, (USD Million) & (KG)
This report profiles key players in the global Milbemycin Oxime API market based on the following parameters - company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Livzon Pharmaceutical Group Inc, Zhejiang Hisun Pharmaceutical Co., Ltd, Hubei Honch Pharmaceutical Co.,Ltd, JIANGSU LINGYUN PHARMACEUTICAL CO.，LTD, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the World Milbemycin Oxime API market
Detailed Segmentation:
Each section contains quantitative market data including market by value (US$ Millions), volume (production, consumption) & (KG) and average price (US$/KG) by manufacturer, by Type, and by Application. Data is given for the years 2021-2032 by year with 2025 as the base year, 2026 as the estimate year, and 2027-2032 as the forecast year.
Global Milbemycin Oxime API Market, By Region:
United States
China
Europe
Japan
South Korea
ASEAN
India
Rest of World
Global Milbemycin Oxime API Market, Segmentation by Type:
98% Purity
Purity Greater than 98%
Global Milbemycin Oxime API Market, Segmentation by Application:
Dog
Cat
Other
Companies Profiled:
Livzon Pharmaceutical Group Inc
Zhejiang Hisun Pharmaceutical Co., Ltd
Hubei Honch Pharmaceutical Co.,Ltd
JIANGSU LINGYUN PHARMACEUTICAL CO.，LTD
Key Questions Answered:
1. How big is the global Milbemycin Oxime API market?
2. What is the demand of the global Milbemycin Oxime API market?
3. What is the year over year growth of the global Milbemycin Oxime API market?
4. What is the production and production value of the global Milbemycin Oxime API market?
5. Who are the key producers in the global Milbemycin Oxime API market?
6. What are the growth factors driving the market demand?
Table of Contents
90 Pages
- 1 Supply Summary
- 2 Demand Summary
- 3 World Manufacturers Competitive Analysis
- 4 United States VS China VS Rest of the World
- 5 Market Analysis by Type
- 6 Market Analysis by Application
- 7 Company Profiles
- 8 Industry Chain Analysis
- 9 Research Findings and Conclusion
- 10 Appendix
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
